<DOC>
	<DOCNO>NCT02556086</DOCNO>
	<brief_summary>The purpose study determine combination therapy daclatasvir ( DCV ) sofosbuvir ( SOF ) 8 week safe effective patient never treat previously without liver cirrhosis chronically infect hepatitis C virus ( HCV ) /HIV-1 Coinfection genotype ( GT ) 1 , 2 , 3 , 4 patient .</brief_summary>
	<brief_title>A Phase 2b Evaluation Daclatasvir/Sofosbuvir Non-Cirrhotic Treatment Naive Subjects With Genotype 1 , 2 , 3 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus ( HIV-1 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com HCV RNA &lt; 2000000 IU/mL Never take medication HCV No Liver Cirrhosis No advance fibrosis Body mass index ( BMI ) 1840 kg/m^2 Genotype 14 Infection HCV GT1 , 2 , 3 GT4 subject mixed infection genotype Evidence decompensated liver Subjects Infected HIV 2 Hepatitis B virus ( HBV ) coinfection Liver Cirrhosis Advanced fibrosis ( F3F4 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>